The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Open-label, phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre- and postmenopausal women with locally advanced or metastatic ER+/HER2− breast cancer and an ESR1 mutation after progression on prior therapies.
 
Senthil Damodaran
Research Funding - EMD Serono (Inst); Guardant Health (Inst); Novartis (Inst); Sermonix Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst)
 
Paul V. Plourde
Employment - Sermonix Pharmaceuticals
Leadership - Sermonix Pharmaceuticals
Stock and Other Ownership Interests - Sermonix Pharmaceuticals
 
Halle C. F. Moore
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Roche (Inst); Sermonix Pharmaceuticals (Inst)
 
Ian Churchill Anderson
Research Funding - Abbvie (Inst); Apollomics (Inst); AstraZeneca (Inst); EMD Serono (Inst); Hutchison MediPharma (Inst); Merck (Inst); Seagen (Inst); Turning Point Therapeutics (Inst)
 
David Jay Portman
Employment - Sermonix Pharmaceuticals
Leadership - Sermonix Pharmaceuticals
Stock and Other Ownership Interests - Sermonix Pharmaceuticals
Consulting or Advisory Role - Agile Therapeutics; Sebela Pharma
Other Relationship - Sermonix Pharmaceuticals (I)